A New Targeted Therapeutic for Multiple Myeloma
A molecularly targeted therapeutic has been approved for treating certain patients with multiple myeloma. Learn more about this recently approved therapy.
Progress Against Cancer
A molecularly targeted therapeutic has been approved for treating certain patients with multiple myeloma. Learn more about this recently approved therapy.
An immunotherapeutic known as a checkpoint inhibitor has been approved for the treatment of certain patients with small-cell lung cancer.
A molecularly targeted therapeutic has been approved to treat some patients with diffuse large B-cell lymphoma the most common type of non-Hodgkin lymphoma.
A combination of an immunotherapy and a molecularly targeted therapy has been approved to treat patients with advanced renal cell carcinoma, kidney cancer.
A molecularly targeted therapeutic has been approved for use in combination with fulvestrant for treating certain men and women with breast cancer.
A combination of an immunotherapy and a targeted therapeutic recently was approved by the FDA for patients advanced renal cell carcinoma (kidney cancer).
A molecularly targeted therapeutic was approved by the FDA to treating certain patients with urothelial carcinoma, the most common form of bladder cancer.
The FDA expanded the use of the immunotherapeutic atezolizumab in combination with carboplatin and etoposide for certain small-cell lung cancer patients.
The FDA approved the immunotherapeutic atezolizumab to treat certain patients who have locally advanced or metastatic triple-negative breast cancer.
The FDA approved a new molecularly targeted therapeutic for patients ages 2 or older who have been diagnosed with a rare type of blood cancer called blastic plasmacytoid dendritic cell neoplasm.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now